Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of paclitaxel polymeric micelles versus physician's choice treatment in previously treated HER2-negative metastatic breast cancer
CTR20232332Phase 3Active
- Sponsor
- Shanghai Yizhong Pharmaceutical Co., Ltd.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of paclitaxel in breast cancer, sponsored by Shanghai Yizhong Pharmaceutical Co., Ltd.. Started Oct 2023; status: active.
02
Drugs
paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20232332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232332.